{"id":"NCT03740737","sponsor":"Ferring Pharmaceuticals","briefTitle":"Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-1)","officialTitle":"A Randomized, Double-blind, Placebo-controlled, Parallel Groups, Multicenter Trial Investigating the Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Women Aged 18-34 Years Undergoing Assisted Reproductive Technology","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-10-26","primaryCompletion":"2020-11-11","completion":"2020-11-11","firstPosted":"2018-11-14","resultsPosted":"2024-01-18","lastUpdate":"2024-01-18"},"enrollment":579,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Infertility"],"interventions":[{"type":"DRUG","name":"Follitropin delta","otherNames":["FE 999049","Rekovelle"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"FE 999049 (Follitropin Delta)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This trial investigates the effects of FE 999049 compared to placebo.","primaryOutcome":{"measure":"Cumulative Ongoing Pregnancy Rate After the Fresh Cycle and Cryopreserved Cycles Initiated Within 12 Months From the Start of COS","timeFrame":"8-9 weeks after transfer (up to approximately 16 months after start of stimulation)","effectByArm":[{"arm":"FE 999049 (Follitropin Delta)","deltaMin":63,"sd":null},{"arm":"Placebo","deltaMin":0,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":12,"exclusionCount":18},"locations":{"siteCount":23,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":525},"commonTop":["Procedural pain","Morning Sickness (Cryopreserved cycle)","Pelvic discomfort","Haemorrhage in pregnancy","Morning sickness (Fresh cycle)"]}}